Search results promise peptides that erase acne scars, often with precise percentages. Most of those numbers do not come from real human trials. The honest version: a couple of topical peptides have reasonable cosmetic evidence for skin texture, while the injectable peptides marketed for scars are unproven for this use and not FDA-approved. This guide separates what has support from what is hype. Regulatory status on this page was reviewed against FDA sources on September 5, 2026.
Do peptides help acne scars?
Answer-first: topical peptides can modestly improve overall skin texture and support collagen, but no peptide is a proven cure for established acne scars, and the injectable ones marketed for scars lack human evidence for this use.
Acne scars, especially atrophic (depressed) ones, come from lost collagen and disrupted tissue. Peptides that signal collagen production have a plausible mechanism, and topical GHK-Cu and palmitoyl peptides have cosmetic research for skin firmness and fine lines. But improving general skin quality is not the same as remodeling a deep scar. Realistic expectations matter: peptides may help texture at the margins, not erase ice-pick or deep boxcar scars. Procedures like microneedling, subcision, or laser remain the evidence-based options for structural scars.
What does copper peptide (GHK-Cu) do for acne scars?
Answer-first: topical GHK-Cu supports collagen and skin remodeling, which can improve overall texture, but strong acne-scar-specific trial data is limited.
GHK-Cu is a copper tripeptide that occurs naturally in the body and is well studied as a topical skin ingredient. Pickart and Margolina's 2018 review (International Journal of Molecular Sciences 2018;19(7):1987) reports that its levels fall with age and summarizes topical studies showing generally modest improvements in skin firmness, elasticity, and appearance. For acne scars specifically, the evidence is more about general skin remodeling than a proven scar cure. Injectable GHK-Cu is a separate matter: it is not FDA-approved, it was removed from FDA's interim Category 2 list on April 22, 2026 (the nominators withdrew it, per the FDA page current as of that date), it is not on the 503A bulks list, and FDA's stated concerns about immunogenicity, peptide-related impurities and the lack of human exposure data still stand.
Does GHK-Cu help with acne scars and is BPC-157 useful?
Answer-first: GHK-Cu may help texture topically; BPC-157 is an unproven, unapproved option for scars.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →BPC-157 is a synthetic 15-amino-acid peptide studied mainly in animals for tissue healing. There are no solid published human trials showing it improves acne scars, and claims of large topical scar reductions are not reliably supported. BPC-157 is not FDA-approved. FDA placed it in interim Category 2 in 2023 over safety concerns, removed it from that list on April 22, 2026, and on July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 (one abstention) to recommend adding it to the 503A bulks list. That recommendation is non-binding; FDA staff opposed it, and rulemaking has to finish before compounding is clearly lawful (PharmExec, July 24, 2026). Anyone seeing BPC-157 marketed as an acne-scar treatment should know it is experimental and unregulated for this purpose.
What about collagen peptides and Matrixyl?
Answer-first: these are the lowest-risk peptide options and best seen as skin support, not scar erasers.
Oral collagen peptides are hydrolyzed collagen supplements sold with skin hydration and elasticity claims; no trial of oral collagen for acne scars was located for the September 2026 update of this page. Matrixyl (palmitoyl pentapeptide-4) is a topical peptide sold with cosmetic claims, not drug claims, for fine lines and texture. Both are sold as supplements or cosmetics rather than drugs, so they avoid the regulatory issues of injectable peptides. For scars, expect gradual, modest skin-quality improvement at best.
Injectable peptides marketed for scars: TB-4 and Epithalon
Answer-first: these are experimental, unapproved, and not supported by human acne-scar trials.
Thymosin Beta-4 (and the related TB-500) and Epithalon are sometimes marketed for deep scar repair. The evidence is largely animal or theoretical, not human acne-scar trials. Both the thymosin beta-4 fragment (TB-500) and Epitalon were placed in FDA interim Category 2, removed from it on April 22, 2026, and recommended by the FDA advisory committee for 503A consideration on July 23 and July 24, 2026 respectively. Neither is approved, and neither can be assumed compoundable until FDA completes rulemaking. Injecting unapproved peptides of uncertain purity for cosmetic scarring carries real risk for unproven benefit.
Comparison table
| Peptide | Use for scars | Human evidence (acne scars) | Route | Regulatory status |
|---|---|---|---|---|
| GHK-Cu | Skin texture support | Limited, mostly general skin | Topical / injectable | Topical: cosmetic. Injectable: removed from FDA interim Category 2 on April 22, 2026; not approved; not on the 503A bulks list |
| Matrixyl | Texture, fine lines | Limited (cosmetic) | Topical | Cosmetic ingredient |
| Collagen peptides | Skin support | Limited | Oral | Dietary supplement |
| BPC-157 | Marketed, unproven | None solid | Topical / injectable | Not approved; removed from Category 2 April 22, 2026; advisory committee recommended 8 to 6 on July 23, 2026; rulemaking pending |
| Thymosin Beta-4 | Marketed, unproven | None solid | Injectable | Not approved; fragment removed from Category 2 April 22, 2026; advisory committee recommended July 23, 2026; rulemaking pending |
| Epithalon | Marketed, unproven | None solid | Injectable | Not approved; removed from Category 2 April 22, 2026; advisory committee recommended July 24, 2026; rulemaking pending |
Where FormBlends fits in
FormBlends tracks the research on the skin and scar peptides covered here and keeps a clear read on what the evidence supports versus what the marketing claims. This guide is meant to give you that honest picture.
For established acne scars specifically, the strongest evidence sits with procedures rather than any peptide, so a board-certified dermatologist can advise on options like topical retinoids, microneedling, or laser. FormBlends own clinical focus is on compounded semaglutide and tirzepatide GLP-1 programs for weight management, a separate category from scar treatment.
Regulatory status as of September 2026: what changed in April and July
Two FDA actions in 2026 changed how the injectable peptides on this page are regulated, and neither one approved anything.
- April 22, 2026. FDA's page on bulk drug substances that may present significant safety risks (content current as of that date) moved BPC-157, injectable GHK-Cu, the thymosin beta-4 fragment sold as TB-500, Epitalon, and eight other peptides out of interim Category 2 into a table of substances nominated but withdrawn. FDA kept its safety language: concerns about immunogenicity, peptide-related impurities, and the absence of human exposure data. Removal from Category 2 is not authorization to compound.
- July 23 and 24, 2026. FDA's Pharmacy Compounding Advisory Committee met on BPC-157, KPV, TB-500 and MOTS-c (July 23) and on emideltide, Semax and epitalon (July 24), each being considered for the 503A bulks list. Trade press reported the votes: 8 to 6 with one abstention to recommend BPC-157, KPV and TB-500; 7 to 5 with two abstentions for MOTS-c; epitalon and Semax recommended; emideltide rejected 6 to 7. FDA staff recommended against inclusion, noting a single 46-person BPC-157 trial and no human studies of KPV, and said rulemaking of roughly 8 to 12 months would be needed before compounding is unambiguously lawful (PharmExec, July 24, 2026).
Bottom line for acne scars: as of September 5, 2026 none of these peptides is FDA-approved for any use, none is on the 503A bulks list, and no human acne-scar trial exists for any of them.
What the FDA still says about the safety of these peptides
FDA's bulk substances page retains the reasoning it used in 2023 for BPC-157, GHK-Cu (injectable routes), TB-500 and Epitalon: the agency identified risks of immunogenicity, uncertainty about peptide-related impurities, and no meaningful human exposure data. Separately, FDA's statement on unapproved GLP-1 drugs (content current as of September 1, 2026) notes that the agency has issued warning letters to sellers marketing injectable peptides labeled for research use to consumers, and that unapproved injectable products carry a risk of serious harm. For a cosmetic goal like scar texture, that risk profile is hard to justify when topical and procedural options exist.
For athletes: the NCAA lists BPC-157
The NCAA's banned drug classes for the 2026-27 academic year include peptide hormones, growth factors, related substances and mimetics, and the NCAA names BPC-157 as an example in that class alongside erythropoietin, human growth hormone and hCG. A college athlete using a BPC-157 product marketed for scars would be using a banned substance regardless of the reason. Topical GHK-Cu and oral collagen are not named on the list.
Frequently asked questions
Do peptides really work for acne scars?
Topical peptides may modestly improve skin texture, but no peptide is a proven cure for established scars. Injectable peptides marketed for scars lack human evidence.
What does copper peptide do for acne scars?
Topical GHK-Cu supports collagen and skin remodeling, which can help overall texture. Strong acne-scar-specific trial data is limited.
Is BPC-157 good for acne or acne scars?
There are no solid human trials supporting BPC-157 for acne or scars. It is not FDA-approved. FDA flagged it as a compounding safety risk in 2023, removed it from the interim Category 2 list on April 22, 2026, and its advisory committee voted 8 to 6 on July 23, 2026 to recommend it for the 503A bulks list; FDA had not acted on that recommendation as of September 5, 2026.
Are peptides better than microneedling or laser for scars?
No. Procedures like microneedling, subcision, and laser have stronger evidence for structural acne scars. Peptides are at best a supporting measure.
Which peptide is safest for scars?
Topical options like GHK-Cu and Matrixyl, and oral collagen peptides, carry the least risk because they are cosmetics or supplements, not injectables.
Can I inject peptides to fix deep scars?
Injectable peptides like TB-4 and Epithalon are unapproved, of uncertain purity, and unproven for acne scars. The risk is real and the benefit unproven.
Did the FDA approve BPC-157 or TB-500 in 2026?
No. On July 23, 2026 FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend BPC-157 and TB-500 for the 503A bulks list, which would allow pharmacies to compound them if FDA agrees and finishes rulemaking. FDA staff opposed the recommendation, it is non-binding, and as of September 5, 2026 neither peptide is FDA-approved or on the bulks list (PharmExec, July 24, 2026; FDA advisory committee calendar).
Is it legal for a pharmacy to compound BPC-157 or GHK-Cu injections right now?
Not clearly. FDA removed BPC-157, injectable GHK-Cu, TB-500 and Epitalon from its interim Category 2 list on April 22, 2026, but removal is not authorization to compound. Compounding under section 503A generally requires a substance to be an approved drug component, have a USP monograph, or appear on the 503A bulks list; these peptides meet none of those as of September 2026, and FDA said rulemaking would take roughly 8 to 12 months.
Related guides
- Can Collagen Peptides Cause Acne? | FormBlends
- 8 Best Peptides for Wound Healing: GHK-Cu, BPC-157, TB-500
- GHK-Cu for Acne Scar Healing: Evidence and Guide
- Does GHK-Cu Help With Acne? Stacking, Retinol & Vitamin C Rules | FormBlends
- Best Healing Peptide Stack: BPC-157 + TB-500 + GHK-Cu
- BPC-157 + GHK-Cu Stack: Benefits, Protocol, and Safety
Sources
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018;19(7):1987, PMID 29986520, PMC6073405.
- American Academy of Dermatology, acne scar treatment overview: https://www.aad.org/public/diseases/acne/derm-treat/scars
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (peptides moved to nominated but withdrawn), content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, epitalon), docket FDA-2025-N-6895. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Pharmaceutical Executive. FDA advisory committee votes to loosen restrictions on four peptides (8-6 BPC-157, KPV, TB-500; 7-5 MOTS-c; rulemaking 8 to 12 months), July 24, 2026. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
- TIME. FDA committee peptides vote (BPC-157 8 yes, 6 no, 1 abstain; emideltide rejected 6-7; FDA staff opposed), July 23, 2026.
- BSR Intelligence (biotechresearch.co.uk). FDA schedules July PCAC review for seven peptides as Category 2 compounding restrictions lapse (twelve peptides removed April 22, 2026). https://www.biotechresearch.co.uk/intelligence/fda-schedules-july-pcac-review-for-seven-peptides-as-category-2-compounding-restrictions-lapse
- NCAA. 2026-27 NCAA Banned Substances (peptide hormones, growth factors, related substances and mimetics; BPC-157 named). https://www.ncaa.org/what-we-do/health-safety-and-performance/anti-doping-and-substance-misuse-prevention/banned-substances
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (warning letters to research-use sellers), content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →